
Opinion|Videos|March 28, 2025
Setting the Stage: Immunotherapy’s Impact and EMPOWER-Lung 1 Study Design
Author(s)Eric K. Singhi, M.D., Ben Creelan, M.D.
Panelists discuss how over the last five years, immunotherapy, particularly PD-1 inhibitors, has revolutionized advanced non-small cell lung cancer (NSCLC) treatment, offering promising first-line therapy options. Prior to the EMPOWER-Lung 1 study, PD-1 inhibitors showed improved survival outcomes as monotherapy. Treatment considerations have since evolved to incorporate patient-specific factors, optimizing therapy based on individual characteristics.
Advertisement
Episodes in this series

Now Playing
Video content above is prompted by the following:
- Over the last five years, how has the emergence of immunotherapy in advanced NSCLC shifted the treatment paradigm in terms of the use of PD-1 inhibitors as first-line therapy?
- Prior to this study, what was known about the survival outcomes of patients receiving PD-1 inhibitors when used as monotherapy in the treatment of advanced NSCLC?
- How have treatment considerations changed regarding the characteristics of patients receiving PD-1 inhibitors since the initiation of this trial?
Advertisement
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Daraxonrasib trial exceeds expectations after decades of disappointment in pancreatic cancer drug development
2
Alyana Samai, M.P.H. | 2026 MHE Emerging Leaders in Healthcare
3
Brukinsa provides long-term disease control in chronic lymphocytic leukemia
4
340B reform and drug shortages are among hospital pharmacy concerns, survey finds
5


























